Physician profile
Ronald F Pendleton
NPI 1689680597
$1,587.44
in general payments reported to CMS, 2019-2025
30 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $119 · 2021: $15.03 · 2022: $105 · 2023: $207 · 2024: $171 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $189.56 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $185.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $152.37 | 2019-2020 | |
| Abbott Laboratories | $145.68 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $101.65 | 2019-2025 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $82.58 | 2019-2022 | |
| Amarin Pharma, INC. | $79.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.34 | 2019-2020 | |
| Pfizer INC. | $50.40 | 2019-2020 | |
| Lilly USA, LLC | $45.84 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $45.35 | 2019-2023 | Linzess |
| Janssen Pharmaceuticals, INC | $40.81 | 2019-2020 | |
| Novo Nordisk INC | $37.93 | 2019-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $27.76 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.57 | 2022-2023 | Xifaxan, Trulance |
| Therapeuticsmd, INC. | $26.89 | 2019 | |
| Bausch Health US, LLC | $24.37 | 2019 | |
| Merck Sharp & Dohme LLC | $22.70 | 2019 | |
| Insulet Corporation | $20.21 | 2023 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $19.40 | 2022 | |
| Daiichi Sankyo INC. | $19.36 | 2025 | Injectafer |
| Genentech USA, INC. | $19.27 | 2019 | |
| Inari Medical, INC. | $17.66 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $16.12 | 2024 | Arexvy, Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $15.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.17 | 2019 | |
| Allergan, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.